Zdrowie i gospodarka · 24/11/2025
FDA to Host Public Meeting on Biosimilar User Fee Act Reauthorization
The FDA is seeking public input and comments on proposed recommendations for reauthorizing the Biosimilar User Fee Act from 2028 to 2032, with a public meeting scheduled to discuss the proposal.